Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 72 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Antipsychotic drugs are widely used to manage behavioral and psychological symptoms in dementia despite concerns about their safety. Objective To examine the association between treatment with antipsychotics (both conventional and atypical) and all-cause mortality. Design Population-based, retrospective cohort study. Setting Ontario, Canada. Patients Older adults with dementia who were followed between 1 April 1997 and 31 March 2003. Measurements The risk for death was determined at 30, 60, 120, and 180 days after the initial dispensing of antipsychotic medication. Two pairwise comparisons were made: atypical versus no antipsychotic use and conventional versus atypical antipsychotic use. Groups were stratified by place of residence (community or long-term care). Propensity score matching was used to adjust for differences in baseline health status. Results A total of 27,259 matched pairs were identified. New use of atypical antipsychotics was associated with a statistically significant increase in the risk for death at 30 days compared with nonuse in both the community-dwelling cohort (adjusted hazard ratio, 1.31 [95% CI, 1.02 to 1.70]; absolute risk difference, 0.2 percentage point) and the long-term care cohort (adjusted hazard ratio, 1.55 [CI, 1.15 to 2.07]; absolute risk difference, 1.2 percentage points). Excess risk seemed to persist to 180 days, but unequal rates of censoring over time may have affected these results. Relative to atypical antipsychotic use, conventional antipsychotic use was associated with a higher risk for death at all time points. Sensitivity analysis revealed that unmeasured confounders that increase the risk for death could diminish or eliminate the observed associations. Limitations Information on causes of death was not available. Many patients did not continue their initial treatments after 1 month of therapy. Unmeasured confounders could affect associations. Conclusions Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia. The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 27,259 participants. In older adults with dementia, starting atypical antipsychotic drugs was linked to a small but significant increase in the risk of death within 30 days. This is a safety concern about symptom-management drugs and does not offer a treatment or cure for dementia itself.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gill, S. S., Bronskill, S. E., Normand, S. L., Anderson, G. M., Sykora, K., Lam, K., et al. (2007). Antipsychotic drug use and mortality in older adults with dementia. Annals of internal medicine. https://doi.org/10.7326/0003-4819-146-11-200706050-00006

Vancouver

Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of internal medicine. 2007. doi:10.7326/0003-4819-146-11-200706050-00006. PMID: 17548409.

BibTeX

@article{gill2007-17548409,
  author  = {Gill, S. S. and Bronskill, S. E. and Normand, S. L. and Anderson, G. M. and Sykora, K. and Lam, K. and Bell, C. M. and Lee, P. E. and others},
  title   = {{Antipsychotic drug use and mortality in older adults with dementia}},
  journal = {Annals of internal medicine},
  year    = {2007},
  doi     = {10.7326/0003-4819-146-11-200706050-00006},
  pmid    = {17548409},
  url     = {https://doi.org/10.7326/0003-4819-146-11-200706050-00006}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In older adults with dementia, starting atypical antipsychotic drugs was linked to a small but significant increase in the risk of death within 30 days. This is a safety concern about symptom-management drugs and does not offer a treatment or cure for dementia itself.

Study details

How this study scored 72/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 4 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 3 of 6; Still being cited 3 of 4; Senior author's track record 3 of 4; Institution's track record 3 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 72 of 100.72 of 100 points earned28 not earned

Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Annals of internal medicine)
Journal's citation record 4 / 4 Annals of Internal Medicine: journal h-index 648 (OpenAlex, 2026-10-29)
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2007 — within 20 year(s) of the newest study here
Sample size 4 / 4 27,259 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 625 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 29.8 citations a year over 21 year(s) since 2007
Impact for its field and year 5 / 6 Cited 23.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 3 / 6 Cited by 11 other studies in this library
Still being cited 3 / 4 Cited 53 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Paula A. Rochon: h-index 86 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 17548409)
Free to read 0 / 2 Behind a paywall — scores zero
Total 72 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in How common it is from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →